1266 Federal Register / Vol. 83, No. 7 / Wednesday, January 10, 2018 / Notices 

Agenda: Discussion of program and issues. 

Place: Nat. Inst. of Environmental Health 

Sciences, Building 101, Rodbell Auditorium, 

111 T. W. Alexander Drive, Research 

Triangle Park, NC 27709. 

Contact Person: Gwen W Collman, Ph.D., 

Interim Director, Division of Extramural 

Research & Training National Institutes of 

Health, Nat. Inst. of Environmental Health 

Sciences, 615 Davis Dr., KEY615/3112, 

Research Triangle Park, NC 27709 (919) 541– 

4980, collman@niehs.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niehs.nih.gov/dert/c-agenda.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: January 4, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–00220 Filed 1–9–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; ‘‘Induction of mucosal 

immune responses for parenterally delivered 

vaccines’’. 

Date: February 5, 2018. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Eleazar Cohen, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

Room 3G62A, National Institute of Health, 

NIAID, 5601 Fishers Lane, MSC 9823, 

Bethesda, MD 20892–9823, (240) 669–5081, 

ecohen@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; (PHS 2018–1) Small 

Business Innovation Research (SBIR) 

Program Contract Solicitation (Topic 53) 

(N01). 

Date: February 6, 2018. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Vasundhara Varthakavi, 

DVM, Ph.D., Scientific Review Officer, 

Scientific Review Program, Division of 

Extramural Activities, Room 3E70, National 

Institutes of Health, NIAID, 5601 Fishers 

Lane, MSC 9823, Bethesda, MD 20892–9823, 

(240) 669–5020, varthakaviv@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 4, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–00217 Filed 1–9–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Drug Abuse. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: February 6, 2018. 

Closed: 9:00 a.m. to 10:15 a.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Open: 10:30 a.m. to 4:30 p.m. 

Agenda: This portion of the meeting will 

be open to the public for announcements and 

reports of administrative, legislative, and 

program developments in the drug abuse 

field. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Susan R.B. Weiss, Ph.D., 

Director, Division of Extramural Research, 

Office of the Director, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, NSC, Room 5274, MSC 9591, 

Rockville, MD 20892, 301–443–6487, 

sweiss@nida.nih.gov. 

Any member of the public interested 

in presenting oral comments to the 

committee may notify the Contact 

Person listed on this notice at least 10 

days in advance of the meeting. 

Interested individuals and 

representatives of organizations may 

submit a letter of intent, a brief 

description of the organization 

represented, and a short description of 

the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, 

presentations may be limited to five 

minutes. Both printed and electronic 

copies are requested for the record. In 

addition, any interested person may file 

written comments with the committee 

by forwarding their statement to the 

Contact Person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.drugabuse.gov/NACDA/ 


daltland on DSKBBV9HB2PROD with NOTICES